

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 February 2023 (23.02.2023)



(10) International Publication Number
WO 2023/021115 A1

(51) International Patent Classification:

A61K 38/37 (2006.01) A61K 47/24 (2006.01)
A61K 47/10 (2017.01) A61P 7/04 (2006.01)

(21) International Application Number:

PCT/EP2022/073013

(22) International Filing Date:

17 August 2022 (17.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2111758.5 17 August 2021 (17.08.2021) GB

(71) Applicant: **CANTAB BIOPHARMACEUTICALS
PATENTS LIMITED** [MT/MT]; Palazzo Pietro Stiges,
103 Strait Street, Valetta, VLT 1436 (MT).

(72) Inventor: **WOLF-GARRAWAY, Richard**; c/o Ascension
Healthcare plc, 31a St. James's Square, London SW1Y 4JR
(GB).

(74) Agent: **BASSIL, Nicholas**; Kilburn & Strode LLP, Lacon
London 84 Theobalds Road, London WC1X 8NL (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: MODIFIED COLLOIDAL PARTICLES FOR USE IN THE TREATMENT OF HAEMOPHILIA A

(57) Abstract: The present invention relates to the use of colloidal particles for the treatment of haemophilia A in patients previously untreated or patients minimally treated with Factor VIII (FVIII). The invention also relates to compositions, methods, kits and dosage forms comprising colloidal particles for treating haemophilia A in patients previously untreated or patients minimally treated with Factor VIII (FVIII).



WO 2023/021115 A1